张大伟 制图 ◎记者 何昕怡 受益于行业景气度日渐回暖、海外市场持续开拓、医药利好政策陆续落地，A股生物医药公司2025年在 韧性发展中不断交出创新的成绩单。 Wind数据显示，截至1月26日18时，已有超过90家A股生物医药公司发布2025年业绩预告，共有53家公 司预计实现盈利。从预告净利润增幅下限来看，有14家公司预计净利润倍增（剔除扭亏、减亏）。此 外，以岭药业、楚天科技等10家公司预计实现扭亏为盈，迪哲医药、盟科药业等14家公司同比实现减 亏。 其中，纳微科技核心业务中色谱填料和层析介质产品2025年销售收入预计实现约23%的增长，液相色谱 柱及样品前处理产品销售收入实现约32%的增长。公司持续加大国际市场拓展力度，预计实现国际业务 收入约8400万元，同比增长约79%。 国际化助力开拓增量市场 国际化业务是生物医药企业业绩增长的另一个助推器。 2025年初以来，受益于创新药行业发展、订单复苏明显，CXO公司表现强劲。作为CXO龙头，药明康 德预计：2025年实现营业收入454.56亿元，同比增长约15.84% ；实现归母净利润191.51亿元，同比增长 102.65%。 销售放量拉动业绩增长 在目 ...

证券之星消息，1月21日化学制药板块较上一交易日下跌0.05%，向日葵领跌。当日上证指数报收于 4116.94，上涨0.08%。深证成指报收于14255.12，上涨0.7%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 002437 | 营衡药业 | 2.06亿 | 29.69% | -9861.41万 | -14.23% | -1.07 Z | -15.46% | | 000766 通化金马 | | 7479.15万 | 14.69% | -3005.02万 | -5.90% | -4474.13万 | -8.79% | | 600196 | 复星医药 | 6434.59万 | 14.11% | 662.83万 | 1.45% | -7097.43万 | -15.56% | | 300401 | 花园生物 | 4966.98万 | 4.97% | -837.33万 | -0.84% ...

业绩增长的主要原因包括公司核心产品销量大幅增长，内部管理加强以及成本控制成效显著。此外，公 司在2025年12月收到出售广州誉衡生物科技有限公司股权的尾款及利息1.32亿元，这一款项计入投资收 益，属于非经常性损益。公司与会计师事务所就业绩预告相关财务数据进行了预沟通，双方不存在分 歧。 近日，誉衡药业发布公告称，预计公司2025年度业绩将显著增长，归母净利润预计为3.5亿元至4.2亿 元，比上年同期的2.33亿元增长50.37%至80.44%。 (编辑：杨燕 林辰)关键字： 医疗 （誉衡药业公告） ...

（文章来源：证券时报网） 资金面上看，誉衡药业近5日主力资金总体呈净流出状态，累计净流出3697.33万元，其中，上一交易日 主力资金全天净流出2380.00万元。 融资融券数据显示，该股最新（1月20日）两融余额3.16亿元，其中，融资余额为3.16亿元，近5日融资 余额合计减少1111.24万元，降幅为3.39%。（数据宝） 誉衡药业股价出现异动，截至今日9时31分，股价涨停，成交4836.66万股，成交金额1.66亿元，换手率 为2.30%，涨停板封单金额为7.93亿元，公司发布的最新业绩预告显示，预计2025年实现净利润3.50亿 元—4.20亿元，净利润同比增长50.37%—80.44%。 证券时报·数据宝统计显示，今日公布2025年业绩预告公司中，截至发稿股价较为强势的有中熔电气、 誉衡药业等，股价分别上涨19.27%、10.03%。 ...

（文章来源：证券时报网） 证券时报·数据宝统计显示，誉衡药业今日收于3.19元，下跌0.62%，日换手率为1.82%，成交额为1.22亿 元，近5日下跌1.54%。通过对2025年业绩预增50%以上的个股走势进行统计发现，预告发布后当日股价 上涨的占比67.06%，股价发布当日股价涨停的有3家。预告发布后5日股价上涨的占比75.29%。 资金面上，该股今日主力资金净流出2380.00万元，近5日资金净流出3697.33万元。最新（1月19日）两 融余额3.22亿元，其中，融资余额3.22亿元，环比前一交易日下降1.54%，近5日融资余额累计下降 1.06%。（数据宝） 誉衡药业（002437）1月20日发布2025年业绩预增公告，预计实现净利润为3.50亿元~4.20亿元，净利润 同比增长50.37%~80.44%。 ...

1．财政部副部长廖岷在国新办新闻发布会上表示，财政部门将继续实施更加积极的财政政策。概括起 来就是"总量增加、结构更优、效益更好、动能更强"。2026年财政赤字、债务总规模和支出总量将保持 必要水平，确保总体支出力度只增不减。 2.财政部副部长廖岷在国新办新闻发布会上表示，本次优化调整个人消费贷款贴息政策，将信用卡账单 分期业务纳入到了贴息范围，取消现有政策当中对一些消费领域的限制。新政策意味着只要是消费贷款 都可以享受贴息。 重要的消息有哪些 1月21日（周三）申购提示 新股方面，美德乐申购代码920119，发行价格41.88元/股 ，发行市盈率为14.99倍，单一账户申购上限为 72万股。 投资有风险，申购需谨慎。 4.财政部等部门发布关于延续实施养老、托育、家政等社区家庭服务业税费优惠政策的公告，为社区提 供养老、托育、家政等服务的机构，按照规定享受税费优惠政策。 3.财政部综合司司长李先忠在国新办新闻发布会上表示，近期财政部、税务总局发布公告，明确自2026 年4月1日起取消光伏等产品出口退税，并分两年取消电子产品出口退税。此次出口退税政策调整，有利 于促进资源高效利用，也有利于引导产业结构合理调整， ...

证券日报网讯 1月20日，誉衡药业发布2025年度业绩预增公告称，公司预计2025年度归属于上市公司股 东的净利润为35，000.00万元至42，000.00万元，比上年同期增长50.37%至80.44%。 （文章来源：证券日报） ...

Core Viewpoint - Yuheng Pharmaceutical (002437) expects a significant increase in net profit for 2025, projecting a range of CNY 350 million to CNY 420 million, representing a year-on-year growth of 50.37% to 80.44% [1] Group 1: Financial Performance - The company anticipates a net profit attributable to shareholders of CNY 350 million to CNY 420 million for 2025, compared to CNY 233 million in the previous year [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between CNY 185 million and CNY 220 million, reflecting a growth of 0.92% to 20.02% from CNY 183 million in the previous year [1] Group 2: Product Development and Market Position - Yuheng Pharmaceutical focuses on the research, production, and sales of pharmaceuticals, with a strong emphasis on high-barrier generic drugs, including pre-filled methotrexate injection [1] - The company has over 300 drug registration certificates, covering various therapeutic areas such as musculoskeletal, cardiovascular, vitamins and minerals, diabetes, analgesics, anti-infection, and anti-tumor [1] - Key products like multi-vitamin injections, potassium chloride sustained-release tablets, and others have maintained high market shares in their respective segments [2] Group 3: Sales and Marketing Strategy - The company primarily sells prescription drugs through hospitals, with some products available in retail pharmacies and e-commerce platforms [2] - Yuheng Pharmaceutical employs a refined招商 (investment promotion) and specialized academic promotion strategy for sales [2] - The company has a low export business proportion, currently limited to sodium phosphate injection to Uzbekistan, with future plans to expand exports in line with the Belt and Road Initiative [2] Group 4: Operational Efficiency - The company has achieved notable results in cost reduction and efficiency improvement, with decreases in both sales and management expenses compared to the same period in 2024 [3] - A non-recurring gain of CNY 132 million from the sale of equity in Guangzhou Yuheng Biotechnology Co., Ltd. is expected to be included in the 2025 investment income [3]

Core Viewpoint - The company expects a significant increase in net profit for 2025, projecting a range of 350 million to 420 million yuan, representing a year-on-year growth of 50.37% to 80.44% [1] Financial Performance - The basic earnings per share are estimated to be between 0.1597 yuan and 0.1917 yuan [1] - The increase in performance is attributed to strong sales growth of core products, including injectable multivitamins, potassium chloride sustained-release tablets, and other key medications [1] Cost Management - The company has improved internal management, leading to a noticeable reduction in sales and administrative expenses compared to the same period last year [1] Non-Recurring Income - In December 2025, the company received 132 million yuan from the sale of equity in Guangzhou Yuheng Biotechnology Co., Ltd., which will be included in the investment income for 2025 as a non-recurring gain [1]

Core Viewpoint - Yuheng Pharmaceutical (002437.SZ) expects a significant increase in net profit for the fiscal year 2025, projecting a range of CNY 350 million to CNY 420 million, representing a year-on-year growth of 50.37% to 80.44% [1] Financial Performance - The company anticipates a net profit attributable to shareholders of CNY 350 million to CNY 420 million, with a year-on-year increase of 50.37% to 80.44% [1] - The net profit after deducting non-recurring gains and losses is projected to be between CNY 185 million and CNY 220 million, reflecting a growth of 0.92% to 20.02% year-on-year [1] Product Performance - Key products such as injectable multivitamins, potassium chloride sustained-release tablets, and other medications have shown substantial and steady sales growth [1] - Additional products contributing to revenue growth include sitagliptin and metformin sustained-release tablets, flurbiprofen ester injection, and injectable papaverine hydrochloride [1]